user
cart
menu
orderQuote Inquiry / OrdercartCart
letter
Sign InRegister
langEnglisharrow

Inhibitor Screening Kits

Inhibitor screening plays a crucial role in drug development, particularly in the early stages. The process involves screening a large number of candidate molecules to identify those with notable pharmacological effects, which are then further evaluated. To efficiently screen multiple potential inhibitors, rapid and sensitive tools are required.

To efficiently screen multiple potential inhibitors by developing an inhibitor screening platform based on the competitive ELISA method. We offer a series of high-sensitivity inhibitor screening kits that utilize unique in-house biotinylated proteins. These kits are designed for preliminary screening and quality control in drug development, providing researchers with reliable, efficient, and accurate tools for inhibitor screening.

Product Features

Accurate & Reliable: Verified raw materials with high batch-to-batch consistency ensure stable and reliable experimental results.

Easy-to-use & Time-saving: Simple, 4-step ELISA procedure has been pre-validated to eliminate time-consuming method development and validations.

Minimal Matrix Effects: Interfering substances, including DMSO, were studied to ensure kit compatibility with small and macro-molecule inhibitors.

High Repeatability: Kits are highly stable and have minimal lot-to-lot variation and use our site-specific biotin labeling platform.

Overview

Quantity 96 tests
Detection Method Colorimetric
Method Type Competitive ELISA
Applications High-throughput screening antibodies, small molecule inhibitors, peptide, etc.

Schematic Diagram

Notes: The assay employs a simple colorimetric ELISA platform which is based on the competitive binding technique. (The principles between different inhibitor screening kits are slightly different)

The experimental protocol includes 4 short steps:

  • Coat the plate with human PD-L1.

  • Add Human PD-1-Biotin to bind the coated human PD-L1.

  • Add your molecule of interest  to the tests.

  • Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

Finally, the ability of your compound to inhibit PD-1: PD-L1 binding will be determined by comparing OD readings among different experimental groups.

Components

Take PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Kit (EP-101) for example.

ID Components Size
EP101-C01 High-bind Plate 1 plate
EP101-C02 Human PD-L1 25 μg
EP101-C03 Anti-PD-1    Neutralizing Antibody 20 μg
EP101-C04 Human PD-1-Biotin 5 μg
EP101-C05 Streptavidin-HRP 10 μg
EP101-C06 Coating Buffer 12 mL
EP101-C07 10xWashing Buffer 50 mL
EP101-C08 Blocking Buffer 50 mL
EP101-C09 Substrate Solution 12 mL
EP101-C10 Stop Solution 7 mL

Product List

Cat. No.MoleculeProduct DescriptionOrder Now
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order

Supplement Data

Inhibition of PD-1: PD-L1 binding by anti-PD-1 neutralizing antibody measured using the PD-1 [biotinylated]: PD-L1 inhibitor screening ELISA assay pair (Cat. No. EP-101).

Anti-PD-1 neutralizing antibody was diluted from 10 μg/mL to 0.078 μg/ mL (69.628 nM to 0.544 nM) and loaded onto the plate coated by human PD-L1 in the presence of human PD-1-Biotin. Assay was performed according to the protocol in PD-1[Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Inhibition of TL1A [Biotinylated] : DR3 binding by anti-TL1A neutralizing antibody measured using TL1A [Biotinylated] : DR3 inhibitor screening kit (Cat. No. EP-168)

Serial dilutions of Human Anti-TL1A Neutralizing antibody (Catalog # EP168-C04) (1:1 serial dilution, from 5 μg/mL to0.0390625 μg/mL) was added into Human DR3: Biotinylated Human TL1A binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested). For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The example data is for reference only.

Inhibition of IL-4: IL-4 R alpha binding by Human IL-4 measured using IL-4 [biotinylated]: IL-4 R alpha inhibitor screening kit (Cat. No. EP-132).

Serial dilutions of Human IL-4(Catalog # EP132-C03) (1:1 serial dilution, from 5 μg/mL to 0.01 μg/mL (295.86-0.58 nM)) was added into IL-4 R alpha: IL-4-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Inhibition of Integrin α 4 β 7: MAdCAM-1binding by anti-Integrin α 4 β 7 neutralizing antibody measured using Integrin α 4 β 7: MAdCAM-1 [Biotinylated] inhibitor screening kit (Cat. No. EP-155)

Serial dilutions of Anti-Integrin α 4 β 7 Neutralizing antibody (Catalog # EP155-C04) (1:1 serial dilution, from 5 μg/mL to 0.0098μg/mL) was added into Integrin α 4 β 7: Biotinylated MAdCAM-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Don’t see your target here? We provide screening services for other targets!

Related product

Immune-Checkpoint

Interleukin

enzyme

FAQ

Q

What types of inhibitors can be evaluated with these screening kits?

The kits are presented for screening antibodies, small molecules and peptides that disrupt a defined protein–protein interaction. Confirm that the selected kit matches the target pair and compound format.
Q

Which assay formats are available for inhibitor screening?

Both competitive ELISA and TR-FRET kits are listed. ELISA kits use a plate-based colorimetric readout, while TR-FRET products use a homogeneous fluorescence format; follow the protocol for the specific kit.
Q

How does the competitive ELISA inhibition format work?

A target protein is immobilized, a biotinylated binding partner and test molecule are added, and residual binding is detected through streptavidin-HRP and a colorimetric substrate. Reduced signal indicates inhibition under the assay conditions.
Q

What assay considerations differ when screening therapeutic antibodies, peptides, and small-molecule PPI inhibitors?

Antibodies, peptides, and small molecules can differ in binding mechanisms, steric effects, solubility, and potential assay interference. Competitive PPI assays can evaluate their ability to disrupt a defined molecular interaction, provided the candidate is compatible with the assay conditions. ACROBiosystems offers ELISA and TR-FRET inhibitor screening kits for different target pairs, with product-specific validation data that help researchers assess suitability for their candidate molecules.
Q

How can the inhibitory profiles of antibodies targeting multiple ligand–receptor interactions be characterized?

Candidates targeting shared ligands or receptors may inhibit different interactions to varying degrees. For example, anti-PD-1 antibodies can be evaluated against PD-1/PD-L1 and PD-1/PD-L2, while anti-TNF-α antibodies can be assessed against TNF-α/TNFR1 and TNF-α/TNFR2. ACROBiosystems provides target-pair-specific inhibitor screening kits for these interactions, enabling separate concentration–response measurements to characterize inhibitory profiles across related receptor–ligand pairs.
Q

What performance data should be considered when selecting an inhibitor screening kit for reproducible candidate evaluation?

Reproducible inhibitor evaluation depends on a measurable inhibition response, suitable assay controls, and consistent performance across runs. Reference inhibitor dose–response curves, IC50 data, and repeatability evidence help establish confidence in assay performance. ACROBiosystems provides validated inhibitor screening kits with reference inhibition data for selected target interactions and emphasizes batch-to-batch consistency, supporting reliable candidate comparisons under standardized assay conditions.
Q

Which therapeutic pathways and target interactions can be evaluated using ACROBiosystems inhibitor screening kits?

ACROBiosystems offers inhibitor screening kits for immune checkpoints (PD-1/PD-L1, PD-1/PD-L2, CTLA-4/CD80/CD86), cytokine–receptor interactions (TNF-α/TNFR1/TNFR2, IL-4/IL-4Rα, BAFF/BAFFR/TACI), and other therapeutic targets, including CD47/SIRPα, VEGFA/VEGFR, and PCSK9/LDLR. Available competitive ELISA and TR-FRET assays support target-specific inhibition studies across oncology, immunology, inflammation, and metabolic disease research.
  • Background
  • Product Features
  • Overview
  • Schematic Diagram
  • Components
  • Product List
  • Supplement Data
  • Related product
  • FAQ